Immunome to Present at Upcoming March Conferences

Rhea-AI Summary

Immunome (Nasdaq: IMNM), a biotechnology company developing first-in-class and best-in-class targeted cancer therapies, has announced its participation in two major investor conferences in March 2025.

The company will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 1:10 p.m. ET. The conference runs from March 3-5, 2025.

Additionally, Immunome will participate in the Leerink Partners Global Healthcare Conference 2025 on March 10, 2025, at 1:40 p.m. ET. This conference is scheduled for March 10-12, 2025.

Live webcast links for both presentations will be available on the events tab of Immunome's investor website, with replay links accessible for 30 days following the live broadcasts.

Positive

• Immunome is presenting at two major healthcare investor conferences, indicating strong interest from the investment community
• The company focuses on developing first-in-class and best-in-class targeted cancer therapies, positioning it in a high-value therapeutic area
• Providing webcasts shows commitment to transparency with investors
• Participation in prestigious conferences may increase visibility and potential investment opportunities

Negative

• The press release doesn't contain any information about the company's current pipeline or development progress
• No financial updates or business developments were included in the announcement
• The conferences are scheduled for 2025, which means any potential catalyst from these events is far in the future

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences in March 2025:

TD Cowen 45th Annual Health Care Conference
Conference Dates: March 3-5, 2025
Presentation Date/Time: March 4, 2025, 1:10 p.m. ET

Leerink Partners Global Healthcare Conference 2025
Conference Dates: March 10-12, 2025
Presentation Date/Time: March 10, 2025, 1:40 p.m. ET

Live webcast links for both presentations will be available on the events tab of Immunome’s investor website. Replay links of the presentations will also be available on the website for 30 days following the live broadcast.

About Immunome

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, IM-1021, a ROR1 ADC with an active IND, and IM-3050, a FAP-targeted radioligand, which is the subject of an IND expected to be submitted in the first quarter of 2025. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit www.immunome.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expectations regarding progress of its pipeline and timeline for regulatory filings, and other statements regarding forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risks and uncertainties described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 13, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225567152/en/

Investor Contact

Max Rosett

Chief Financial Officer

investors@immunome.com

Source: Immunome, Inc.

FAQ

When will Immunome (IMNM) present at the TD Cowen Health Care Conference in 2025?

Immunome (IMNM) will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 1:10 p.m. ET. The conference runs from March 3-5, 2025.

What time is Immunome's (IMNM) presentation at the Leerink Partners Global Healthcare Conference 2025?

Immunome (IMNM) will present at the Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. ET. The conference is scheduled for March 10-12, 2025.

How can investors access Immunome's (IMNM) March 2025 conference presentations?

Investors can access live webcast links for both presentations on the events tab of Immunome's investor website. Replay links will also be available on the website for 30 days following the live broadcasts.

What type of therapies is Immunome (IMNM) developing according to their March 2025 conference announcement?

According to the announcement, Immunome (IMNM) is a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies.

Where is Immunome (IMNM) headquartered based on their March 2025 conference announcement?

Based on the press release, Immunome (IMNM) is headquartered in Bothell, Washington.